目次

Table of Content

1. Introduction To Bispecific Antibody
1.1 Overview
1.2 Clinical Advancement of Bispecific Antibodies

2. Bispecific Antibodies Combination Strategies
2.1 Chemotherapy
2.2 Targeted Therapy
2.3 Immunotherapies
2.4 Radiotherapy

3. Commercially Approved Bispecific Antibodies Insight
3.1 Company, Indication, Location and MOA
3.2 Bispecific Antibodies Granted FDA and EMA Designations

4. Bispecific Antibodies Proprietary Platforms

5. Global and Regional Bispecific Antibody Market Outlook
5.1 Yearly and Quarterly Sales Insight (2020 to 2024)
5.2 Approved Bispecific Antibodies Reimbursement Policy
5.3 Global Bispecific Antibody Market Forecast 2030

6. Global Bispecific Antibody Market Trends By Region
6.1 Japan
6.2 South Korea
6.3 US
6.4 Europe
6.5 China
6.6 UK
6.7 Australia
6.8 Canada
6.9 Latin America

7. Global Bispecific Antibodies Research and Market Trends By Indications
7.1 Lymphoma
7.2 Multiple Myeloma
7.3 Leukemia
7.4 Lung Cancer
7.5 Melanoma
7.6 Gastrointestinal Cancers
7.7 Other Cancers
7.8 Blood Disorders
7.9 Autoimmune and Inflammatory Diseases
7.10 Microbial Diseases
7.11 Ocular Diseases

8. Blincyto - Clinical, Patent, Pricing and Sales Insight
8.1 Overview and Patent Insight
8.2 Pricing and Dosage Analysis
8.3 Sales Analysis

9. Hemlibra - Clinical, Patent, Pricing and Sales Insight
9.1 Overview
9.2 Pricing and Dosage Insight
9.3 Sales Analysis

10. Rybrevant - Clinical, Patent and Pricing Insight
10.1 Overview
10.2 Pricing and Dosage Insight

11. Vabysmo - Clinical, Patent, Pricing and Sales Insight
11.1 Overview
11.2 Pricing and Dosage Insight
11.3 Sales Analysis

12. Lunsumio - Clinical, Patent, Pricing and Sales Insight
12.1 Overview and Patent Insight
12.2 Pricing and Dosage Insight
12.3 Sales Analysis

13. Kaitani - Clinical and Sales Insight

14. Tecvayli - Clinical, Patent and Pricing Insight
14.1 Overview and Patent Insight
14.2 Pricing and Dosage Insight
14.3 Sales Analysis

15. Columvi - Clinical, Patent, Pricing and Sales Insight
15.1 Overview and Patent Insight
15.2 Pricing and Dosage Insight
15.3 Sales Analysis

16. Epkinly - Clinical, Patent, Pricing and Sales Insight
16.1 Overview
16.2 Pricing and Dosage Insight
16.3 Sales Analysis

17. Talvey - Clinical, Patent and Pricing Insight
17.1 Overview and Patent Insight
17.2 Pricing and Dosage Insight

18. Elrexfio - Clinical, Patent and Pricing Insight
18.1 Overview
18.2 Pricing and Dosage Insight
18.3 Sales Analysis

19. Imdelltra - Clinical, Patent, Pricing and Sales Insight
19.1 Overview and Patent Insight
19.2 Pricing and Dosage Insight
19.3 Sales Analysis

20. Ivonescimab - Clinical Insight

21. Ordspono - Clinical and Sales Insight
21.1 Overview
21.2 Sales Analysis

22. Ziihera - Clinical, Pricing and Sales Insight
22.1 Overview
22.2 Pricing and Dosage
22.3 Sales Insight

23. Bizengri - Clinical, Patent, Pricing and Sales Insight
23.1 Overview
23.2 Dosing and Pricing

24. Korjuny - Clinical Insight

25. Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I
25.4 Phase-I/II
25.5 Phase-II
25.6 Phase-II/III
25.7 Phase-III
25.8 Preregistration
25.9 Registered

26. Marketed Bispecific Antibodies Clinical Insight By Company, Country and Indication

27. Competitive Landscape
27.1 ABL Bio
27.2 Abzyme Therapeutics
27.3 Affimed Therapeutics
27.4 Akeso Biopharma
27.5 Alligator Bioscience
27.6 Amgen
27.7 Antibody Therapeutics
27.8 APITBIO
27.9 Aptevo Therapeutics
27.10 Astellas Pharma
27.11 AstraZeneca
27.12 BioAtla
27.13 Biosion
27.14 Biotheus
27.15 BJ Bioscience
27.16 EpimAb Biotherapeutics
27.17 FutureGen Biopharmaceutical
27.18 Genentech
27.19 Genmab
27.20 Gensun Biopharma
27.21 Harbour BioMed
27.22 IGM Biosciences
27.23 I-MAB Biopharma
27.24 ImmuneOnco Biopharma
27.25 Innovent Biologics
27.26 Invenra
27.27 Janssen Research and Development
27.28 Kenjockety Biotechnology
27.29 LaNova Medicines Limited
27.30 Light Chain Bioscience
27.31 Linton Pharm
27.32 Lyvgen Biopharma
27.33 MacroGenics
27.34 Merus
27.35 NovaRock Biotherapeutics
27.36 Pfizer
27.37 Phanes Therapeutics
27.38 Prestige BioPharma
27.39 Regeneron Pharmaceuticals
27.40 Revitope
27.41 Roche
27.42 Virtuoso Therapeutics
27.43 Xencor
27.44 Y-Biologics
27.45 Zhejiang Shimai Pharmaceutical
27.46 Zymeworks

List of Figures
Figure 1-1: Bispecific Antibodies - Advantages
Figure 2-1: Antibody-Chemotherapy Combination - Advantages
Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
Figure 3-1: Blincyto - Mechanism of Action
Figure 3-2: Hemlibra - Mechanism of Action
Figure 3-3: Rybrevant - Mechanism of Action
Figure 3-4: Regulatory Designations - Benefits
Figure 4-1: Multiclonics - Distinctive Characteristics
Figure 4-2: Biclonics - Format
Figure 4-3: ADAPTIR Bispecific Structure
Figure 4-4: ADAPTIR-FLEX
Figure 4-5: BEAT Platform - Multispecific Antibodies
Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
Figure 4-7: BiClone format
Figure 4-8: BioAtla CABs - Features
Figure 4-9: BioAtla CABs - Benefits
Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 4-12: Novel HBICE
Figure 4-13: HBICE - Mechanism of Action
Figure 4-14: HBICE - Mechanism of Action
Figure 4-15: Phanes Therapeutics - PACbody Platform
Figure 4-16: Phanes Therapeutics - SPECpair Platform
Figure 4-17: Phanes Therapeutics - ATACCbody
Figure 4-18: Numab Therapeutics - Technology
Figure 4-19: Grabody I Platform - Mechanism of Action
Figure 4-20: Grabody I Platform - Mechanism of Action
Figure 4-21: 3-Step DuoBody Production Process
Figure 4-22: DuoHexaBody Molecules - Schematic
Figure 4-23: iTAb - Patented Structure
Figure 4-24: iTAb - Mechanism of Action
Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
Figure 4-26: BiTE - Structure
Figure 4-27: BiTE Molecule
Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 4-29: ALiCE - Characteristics
Figure 4-30: ALiCE - Schematic Diagram and Mechanism of Action
Figure 4-31: Abz2 Bispecific Platform
Figure 4-32: Abz2 Bispecifics - Benefits
Figure 4-33: Neo-X-Prime Bispecific Mechanism
Figure 4-34: B-Body Bispecific Antibody - Structre
Figure 4-35: xLinkBsAb - Structure
Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2024
Figure 5-3: Global - Bispecific Antibodies Market Shares by Drugs (%), 2024
Figure 5-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2024
Figure 5-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2024
Figure 5-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
Figure 5-7: US -Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-9: US - Quarterly Bispecific Antibodies Market (US$ Million),2023
Figure 5-10: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2024
Figure 5-11: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-12: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-13: Global - Bispecific Antibodies Market By Drug (US$ Million), 2023
Figure 5-14: Global - Bispecific Antibodies Market Shares By Drugs (%), 2023
Figure 5-15: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
Figure 5-16: Global - Bispecific Antibody Market By Region (US$ Million), 2023
Figure 5-17: Global - Bispecific Antibody Market Shares By Region (%), 2023
Figure 5-18: Blincyto - Total Treatment Cost and Reimbursement Cost
Figure 5-19: Blincyto - In Pocket and Out of Pocket Cost of Treatment
Figure 5-20: Hemlibra - Total Treatment Cost and Reimbursement Cost
Figure 5-21: Hemlibra - In Pocket and Out Of Pocket Cost Of Treatment
Figure 5-22: Rybrevant - Maximum Coverage By Medicaid (US$), 2023
Figure 5-23: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$), 2021
Figure 5-24: Vabysmo - Total Treatment Cost and Reimbursement Cost
Figure 5-25: Vabysmo - In Pocket and Out Of Pocket Cost Of Treatment
Figure 5-26: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
Figure 6-1: US - Bispecific Antibodies Approval
Figure 7-1: Bispecific Antibodies - Advantages
Figure 7-2: HX009-II-02 Phase 1/2 Study - Initiation and Completion Year
Figure 7-3: Bispecific Antibodies - Future Opportunities in Melanoma
Figure 7-4: Mim8 Phase 3 (NCT05878938) Study - Initiation and Completion Year
Figure 7-5: NXT007 Phase 1/2 (NCT05987449) Study - Initiation and Completion Year
Figure 7-6: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation and Completion Year
Figure 8-1: Blincyto - Approval Year By Region
Figure 8-2: Blincyto - Patent Filing and Expiration Year
Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 8-4: Blincyto - Duration Of Treatment Phase and Resting Phase In Induction and Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
Figure 8-5: Blincyto - Recommended Number Of Induction and Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle and Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2024
Figure 8-8: Global - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-9: Global - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-10: Blincyto - Sales By Region (US$ Million), 2024
Figure 8-11: Blincyto - Sales By Region (%), 2024
Figure 8-12: Blincyto - Sales By Region (US$ Million), 2023
Figure 8-13: Global - Blincyto Sales By Region (%), 2023
Figure 8-14: US - Blincyto Sales ((US$ Million), 2020-2024
Figure 8-15: US - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-16: US - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-17: ROW - Blincyto Sales (US$ Million), 2020-2024
Figure 8-18: ROW - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-19: ROW - Blincyto Sales Quaterly (US$ Million), 2023
Figure 9-1: Hemlibra - Approval Years By Region
Figure 9-2: Hemlibra - Cost per Unit and Supply of 30 mg/mL Subcutaneous Injection Of Different Volumes (US$), March’2025
Figure 9-3: Hemlibra - Cost per Unit and Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March’2025
Figure 9-4: Hemlibra - Recommended Loading and Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
Figure 9-5: Global - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-6: Global - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-7: Global - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-8: US - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-9: US - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-10: US - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-11: Europe - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-12: Europe - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-13: Europe - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-14: Japan - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-15: Japan - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-16: Japan - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-17: ROW - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-18: ROW - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-19: ROW - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-20: Global - US v/s ex-US Sales (US$ Million), 2024
Figure 9-21: Global - Hemlibra Annual Sales By Region (US$ Million), 2024
Figure 9-22: Global - Hemlibra Sales By Region (%), 2024
Figure 9-23: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 9-24: Global - Hemlibra Annual Sales By Region (US$ Million), 2023
Figure 9-25: Global - Hemlibra Sales By Region (%), 2023
Figure 10-1: Rybrevant - Patent Filing and Expiration Year
Figure 10-2: Rybrevant - Price Per Unit and Supply Of Intravenous Solution (US$), March’2025
Figure 10-3: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
Figure 10-4: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
Figure 10-5: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 11-1: Vabysmo - Approval Year By Region
Figure 11-2: Rybrevant - Patent Filing and Expiration Year
Figure 11-3: Vabysmo - Price Per Unit and Supply Of Intravitreal Solution (US$), March’2025
Figure 11-4: Global - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-5: Global - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-6: Global - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-7: US - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-8: US - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-9: US - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-10: Europe - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-11: Europe - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-12: Europe - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-13: Japan - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-14: Japan - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-15: Japan - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-16: ROW - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-17: ROW - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-18: ROW - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-19: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2024
Figure 11-20: Global - Vabysmo Annual Sales by Region (US$ Million), 2024
Figure 11-21: Global - Vabysmo Sales By Region (%), 2024
Figure 11-22: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2023
Figure 11-23: Global - Vabysmo Annual Sales By Region (US$ Million), 2023
Figure 11-24: Global - Vabysmo Sales By Region (%), 2023
Figure 12-1: Lunsumio - Approval Years By Region
Figure 12-2: US - Price Per Unit and Supply of Lunsumio Intravenous Solution (US$), March’2025
Figure 12-3: EU - Price Per Unit and Supply of Lunsumio Intravenous Solution (US$), March’2025
Figure 12-4: Global - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-5: Global - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-6: Global - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-7: US - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-8: US - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-9: US - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-10: Europe - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-11: Europe - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-12: Europe - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-13: ROW - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-14: ROW - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-15: Lunsumio - US v/s Ex-US Sales (US$ Million), 2024
Figure 12-16: Global - Lunsumio Annual Sales By Region (US$ Million), 2024
Figure 12-17: Global - Lunsumio Sales By Region (%), 2024
Figure 12-18: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 12-19: Global - Lunsumio Annual Sales By Region (US$ Million), 2023
Figure 12 20: Global - Lunsumio Sales By Region (%), 2023
Figure 13-1: China - Kaitani Sales (US$ Million), 2022-2023
Figure 13-2: China - Kaitani Sales (US$ Million), H1-H2’2023
Figure 14-1: Tecvayli - Approval Years by Region
Figure 14-2: Tecvayli - Patent Acceptance and Expiration Year
Figure 14-3: US - Cost Per Unit and Supply Of Tecvayli Subcutaneous Solution (US$), March’2025
Figure 14-4: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March’2025
Figure 14-5: Global - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-6: Global - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-7: Global - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-8: US - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-9: US - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-10: US - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-11: ROW - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-12: ROW - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-13: ROW - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-14: Tecvayli - US v/s Ex-US Sales (US$ Million), 2024
Figure 14-15: Tecvayli - US v/s Ex-US Sales (%), 2024
Figure 14-16: Tecvayli - US v/s Ex-US Sales (US$ Million), 2023
Figure 14-17: Tecvayli - US v/s Ex-US Sales (%), 2023
Figure 15-1: Columvi - Approval Year By Region
Figure 15-2: US - Price Per Unit and Supply Of Columvi Intravenous Solution (US$), March’2025
Figure 15-3: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March’2025
Figure 15-4: Global - Columvi Sales (US$ Million), 2023-2024
Figure 15-5: Global - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-6: Global - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-7: US - Columvi Sales (US$ Million), 2023-2024
Figure 15-8: US - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-9: US - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-10: Europe - Columvi Sales (US$ Million), 2023 and 2024
Figure 15-11: Europe - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-12: Europe - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-13: ROW - Columvi Sales (US$ Million), 2023 and 2024
Figure 15-14: ROW - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-15: ROW - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-16: Global - Columvi US v/s Ex-US Sales (US$ Million), 2024
Figure 15-17: Global - Columvi Annual Sales By Region (US$ Million), 2024
Figure 15-18: Global - Columvi Sales By Region (%), 2024
Figure 15-19: Global - Columvi US v/s Ex-US Sales (US$ Million), 2023
Figure 15-20: Global - Columvi Annual Sales By Region (US$ Million), 2023
Figure 15-21: Global - Columvi Sales By Region (%), 2023
Figure 16-1: Epkinly - Approval Year By Region
Figure 16-2: US - Cost Per Unit and Supply Of Epkinly Subcutaneous Solution (US$), March’2025
Figure 16-3: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March’2025
Figure 16-4: Global - Epkinly Sales (US$ Million), 2023 and 2024
Figure 16-5: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023 and 2024
Figure 16-6: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023 and 2024
Figure 16-7: Global - Epkinly Sales By Company (US$ Million), 2024
Figure 16-8: Global - Epkinly Sales By Company (US$ Million), 2023
Figure 17-1: Talvey - Approval Year By Region
Figure 17-2: Talquetamab - FDA and EMA Designation Year
Figure 17-3: Talvey - Patent Acceptance and Expiration Year
Figure 17-4: US - Price Per Unit and Supply Of Talvey Intravenous Solution (US$), March’2025
Figure 17-5: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March’2025
Figure 18-1: Elrexfio - Approval Year by Region
Figure 18-2: Elranatamab - FDA and EMA Designation Year
Figure 18-3: US - Price Per Unit and Supply Of Elrexfio Subcutaneous Solution (US$), March’2025
Figure 18-4: Global - Elrexfio Sales (US$ Million), 2023 and 2024
Figure 18-5: US - Elrexfio Sales (US$ Million), 2023 and 2024
Figure 18-6: ROW - Elrexfio Sales (US$ Million), 2023 and 2024
Figure 19-1: Imdelltra - Approval Year By Region
Figure 19-2: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March’2025
Figure 19-3: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March’2025
Figure 19-4: Global - Imdelltra Sales (US$ Million), 2024
Figure 19-5: Global - Imdelltra Sales Quaterly (US$ Million), 2024
Figure 21-1: Global - Ordspono Sales (US$ Million), 2022-2024
Figure 21-2: Global - Ordspono Sales Quaterly (US$ Million), 2024
Figure 22-1: US - Price Per Unit and Supply Of Ziihera (US$), March’2025
Figure 22-2: Global - Ziihera Sales (US$ Million), 2024
Figure 23-1: Zenocutuzumab - Active Patents

List of Tables
Table 2-1: Bispecific Antibody and Chemotherapy Combinations in Clinical Trials
Table 2-2: Bispecific Antibody and Targeted Therapy Combinations in Clinical Trials
Table 2-3: Bispecific Antibody and Immunotherapy Combinations in Clinical Trials
Table 2-4: Bispecific Antibody and Radiotherapy Combinations in Clinical Trials
Table 3-1: Approved Bispecific Antibodies
Table 3-2: US - Bispecific Antibodies with Regulatory Designations
Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
Table 3-4: China - Bispecific Antibodies with Regulatory Designations
Table 5-1: Epkinly - Billing Unit Application For Doses
Table 5-2: Talvey - Coverage Summary
Table 5-3: Talvey - Coding Summary
Table 5-4: Elrexfio - HCPCS Codes
Table 5-5: Elrexfio - HCPCS Modifiers
Table 5-6: Imdelltra - Payer Coverage and Reimbursement Details
Table 5-7: Ziihera - ICD-10-CM Codes
Table 5-8: Ziihera - ICD-10-PCS Codes
Table 6-1: US - Some FDA Designated Bispecific Antibodies
Table 6-2: US - Bispecific Antibodies With Recent IND Clearances
Table 6-3: EU - Bispecific Antibodies in Late Stage Clinical Trials
Table 6-4: Latin America - Bispecific Antibodies in Clinical Trials
Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
Table 7-6: Gastrointestinal Cancers - Bispecific Antibodies in Clinical Trials
Table 8-1: Blincyto - Active Patents
Table 8-2: Blincyto - Recommended Dosage and Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
Table 8-3: Blincyto - Recommended Dosage and Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 8-4: Blincyto - Recommended Dosage and Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 10-1: Rybrevant - Premedication
Table 10-2: Rybrevant - Dose Reductions For Adverse Reactions
Table 10-3: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
Table 12-1: Lunsumio - Recommended Treatment Cycles
Table 12-2: Lunsumio - Recommended Premedications
Table 12-3: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
Table 14-1: Tecvayli - Dosing Schedule
Table 14-2: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
Table 15-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 15-2: Columvi - Premedications To Be Administered
Table 15-3: Columvi - Recommendations For Management Of Cytokine Release Syndrome
Table 15-4: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
Table 15-5: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
Table 16-1: Epkinly - Dosage Schedule
Table 16-2: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
Table 16-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 16-4: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
Table 17-1: Talvey - Weekly Dosing Schedule
Table 17-2: Talvey - Biweekly Dosing Schedule
Table 17-3: Talvey - Recommendations for Management of CRS
Table 17-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 17-5: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
Table 17-6: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
Table 18-1: Elrexfio - Dosing Schedule
Table 18-2: Elrexfio - Recommendations For Management Of CRS
Table 18-3: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
Table 22-1: Ziihera - Dosage Modifications For Adverse Reactions
Table 23-1: Bizengri - Premedications Prior To Infusions
Table 23-2: Bizengri - Recommended Dosage Modifications and Management For Adverse Reactions